The biotechnology company Bio-Works states in an operational update that developments are following the company's strategy with improved financial performance, increased commercial activity, and a plan that is fully funded through break-even.The company is strengthening its position in biological applications such as purification of peptides, oligonucleotides, and monoclonal antibodies. The products are used in around a hundred drug projects and in over 20 commercial manufacturing programs globally. Bio-Works has identified five major business opportunities in Europe, North America, and Asia and sees a potential contribution of SEK 250–500 million over the next three to five years.